国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
MediaPortfolio Companies
国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
July 29, 2025

Press Release
Portfolio Companies
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
Cambridge, Mass., June 19, 2026

Press Release
Portfolio Companies
Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient
San Diego, October 21, 2025
